Abstract
Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Current Neuropharmacology
Title: Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Volume: 8 Issue: 2
Author(s): Alberto Spalice, Pasquale Parisi, Laura Papetti, Francesco Nicita, Fabiana Ursitti, Francesca Del Balzo, Enrico Properzi, Alberto Verrotti, Martino Ruggieri and Paola Iannetti
Affiliation:
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Export Options
About this article
Cite this article as:
Spalice Alberto, Parisi Pasquale, Papetti Laura, Nicita Francesco, Ursitti Fabiana, Del Balzo Francesca, Properzi Enrico, Verrotti Alberto, Ruggieri Martino and Iannetti Paola, Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update, Current Neuropharmacology 2010; 8 (2) . https://dx.doi.org/10.2174/157015910791233141
DOI https://dx.doi.org/10.2174/157015910791233141 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Not Only a Clinical Nightmare: Amniotic Fluid Embolism in Court
Current Pharmaceutical Biotechnology Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Adverse Drug Reactions in Critical Care Settings: A Systematic Review
Current Drug Safety Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects
Drug Metabolism Letters Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Antimicrobial Resistance in the 21st Century: A Multifaceted Challenge
Protein & Peptide Letters Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design